Huntington's disease clinical trials corner: February 2018

Journal of Huntington's Disease

Volumn 7, Issue 1, 2018, Pages 88-97

  Rodrigues, Filipe B ^a,b,c   Wild, Edward J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^c INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

Author keywords

Clinical trials; Huntington disease

Indexed keywords

ARTICLE; CLINICAL TRIAL (TOPIC); HUNTINGTON CHOREA; INFORMATION; PRIORITY JOURNAL; HUMAN; REGISTER; TREATMENT OUTCOME;

DEUTETRABENAZINE; TETRABENAZINE;

CLINICAL TRIALS AS TOPIC; HUMANS; HUNTINGTON DISEASE; REGISTRIES; TETRABENAZINE; TREATMENT OUTCOME;

EID: 85043571458     PISSN: 18796397     EISSN: 18796400     Source Type: Journal    
DOI: 10.3233/JHD-189001     Document Type: Article

References (21)

1. Ionis Pharmaceuticals I. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS-HTTRx in PatientsWith Early Manifest Huntingtons Disease. https://ClinicalTrials.gov/show/NCT02519036; 2015.
2. Wave Life Sciences. Safety and Tolerability of WVE-120101 in Patients With Huntingtons Disease. https://ClinicalTrials.gov/show/NCT03225833; 2017.
3. Wave Life Sciences. Safety and Tolerability of WVE-120102 in Patients With Huntingtons Disease. https://ClinicalTrials.gov/show/NCT03225846; 2017.
4. Teva Pharmaceutical Industries. First Time Use of SD-809 in Huntington Disease. https://ClinicalTrials.gov/show/NCT01795859; 2013.
5. Huntington Study Group. Effect of deutetrabenazine on chorea among patients with huntington disease: A randomized clinical trial. Jama. 2016;316(1):40-50.
6. Rodrigues FB, Wild EJ. Clinical trials corner: September 2017. J Huntingtons Dis. 2017;6(3):255-63.
7. Ionis Pharmaceuticals I. Ionis Pharmaceuticals Licenses IONIS-HTT Rx to Partner Following Successful Phase 1/2a Study in Patients with Huntingtons Disease 2017 [Available from: http://ir.ionispharma.com/newsreleases/news-release-details/ionis-pharmaceuticals-licens es-ionis-htt-rx-partner-following
8. The Guardian. Excitement as trial shows Huntingtons drug could slow progress of disease 2017 [Available from: https://www.theguardian.com/science/2017/dec/11/excitem ent-As-huntingtons-drug-shown-To-slow-progress-of-devas tating-disease
9. CNN. Drug trial shows promising results to fight Huntingtons disease 2017 [Available from: http://edition.cnn. com/2017/12/11/health/huntingtons-disease-drug-Trial-stu dy/index.html
10. HDSA. Breaking news: update on the status of the IONIS-HTTRX program and its future 2017 [Available from: http://hdsa.org/news/breaking-news-update-on-Thestatus-of-The-ionis-httrx-program-And-its-future/
11. Ionis Pharmaceuticals I. Study in Huntingtons Disease Patients Who Participated in Prior Investigational Studies of ISIS 443139. https://ClinicalTrials.gov/show/NCT03342053; 2017.
12. Wild EJ, Tabrizi SJ. Therapies targeting DNA and RNA in Huntingtons disease. Lancet Neurol. 2017;16(10):837-47.
13. Kay C, Collins JA, Skotte NH, Southwell AL, Warby SC, Caron NS, et al. Huntingtin haplotypes provide prioritized target panels for allele-specific silencing in huntington disease patients of european ancestry. Molecular Therapy. 2015;23(11):1759-71.
14. Saudou F, Humbert S. The biology of huntingtin. Neuron. 2016;89(5):910-26.
15. Iwamoto N, Butler DCD, Svrzikapa N, Mohapatra S, Zlatev I, Sah DWY, et al. Control of phosphorothioate stereochemistry substantially increases the efficacy of antisense oligonucleotides. Nature biotechnology. 2017;35(9): 845-51.
16. Frank S, Testa CM, Stamler D, Kayson E, Davis C, Edmondson MC, et al. Effect of deutetrabenazine on chorea among patients with Huntington disease: A randomized clinical trial. Jama. 2016;316(1):40-50.
17. Auspex Pharmaceuticals I. Alternatives for Reducing Chorea in HD. 2013.
18. Frank S, Stamler D, Kayson E, Claassen DO, Colcher A, Davis C, et al. Safety of converting from tetrabenazine to deutetrabenazine for the treatment of chorea. JAMANeurol. 2017;74(8):977-82.
19. Rodrigues FB, Duarte GS, Costa J, Ferreira JJ, Wild EJ. Tetrabenazine versus deutetrabenazine for Huntingtons disease: Twins or distant cousins? Mov Disord Clin Pract. 2017;4(4):582-5.
20. Claassen DO, Carroll B, De Boer LM, Wu E, Ayyagari R, Gandhi S, et al. Indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease. J Clin Mov Disord. 2017;4:3.
21. Rodrigues FB, Duarte GS, Costa J, Ferreira JJ, Wild EJ. Meta-research metrics matter: Letter regarding article "indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease". J Clin Mov Disord. 2017;4(9):19